The partnering event BIO-Europe has been a vital hub for the life science industry, fostering knowledge exchange and networking for three decades. This year, delegates gather in Stockholm, and BioStock is on-site as a media partner, connecting with company leaders, innovators, and experts. Watch our interviews below.

EBD Group’s BIO-Europe, now in its 30th year, continues to consolidate its role as one of the life science industry’s most important meeting points. With over 30,000 one-to-one meetings scheduled, the event offers a comprehensive lineup of workshops, presentations, and panel discussions that explore the industry’s future and the latest research advances.

Investors are crowding the congress floor

Among the attendees, BioStock met with Dr. Gene Cho, Managing Partner of the new US-based VC fund Valuence Ventures, which primarily focus on enabling tools and technologies, including AI-driven innovation. So far this year, the fund has made five investments, with another two to three anticipated by year’s end, and several more planned for 2025.

Speaking with BioStock’s Natasha Bank, Cho shares his views on the significant investment opportunities Valuence Ventures sees in the European region. When asked what makes an investment case stand out, he highlighted the importance of presenting a strong go-to-market strategy, even in the early stages of development. Watch the interview here.

We also spoke with Ted Fjällman, CEO of Flerie Invest, who shared insights into the investment strategy of the recently listed fund, which currently boasts a portfolio of 29 companies. The fund specialises in long-term investments and views itself more as a company builder than a traditional investor. Watch the interview here.

Lydia Kalafateli, Venture Developer & Lead Biotech at Dutch firm NLC Health Ventures, shared the fund’s focus on early-stage programs. NLC often gets onboard during the development phase, supporting both the founding and financing of new life science companies. With a portfolio of around 100 companies, NLC is attending BIO-Europe to explore new investment opportunities as well as partnerships for its existing portfolio. Watch the interview here.

Interesting companies attract attention

At BIO-Europe, numerous life science companies seek partnerships, including ExpreS2ion Biotechnologies, which explores partnering opportunities while preparing for phase I with its breast cancer vaccine candidate, ES2B-C001. CEO Bent U. Frandsen told BioStock that initiating discussions early is essential to build relationships with potential partners, increasing the chances of securing a favourable agreement down the line.

Also present is Professor Carl Borrebaeck, Chairman of the Board at PainDrainer and a precision medicine veteran with extensive biotech innovation experience. In our interview, he discusses PainDrainer’s progress in AI-driven solutions designed to offer personalised support for patients with chronic pain. With both regulatory approval and reimbursement status in the U.S., Borrebaeck remains confident of Paindrainer’s potential for continued growth.

Prenumerera på BioStocks nyhetsbrev